First-of-its-Kind cell therapy trial targets devastating muscle disease
NCT ID NCT07086404
Summary
This is a very early study to see if a new type of cell therapy called GC012F is safe and might help adults with a severe form of inflammatory muscle disease that hasn't responded to other treatments. Doctors will collect a patient's own immune cells, modify them in a lab to potentially fight the disease, and then infuse them back. The main goal is to check for serious side effects and see how the body handles the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY (IIM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital of Tongji Medical Colledge, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact
Conditions
Explore the condition pages connected to this study.